Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10x GenomicsTXG +1.96%56 EV-to-OCF is 63.04 as of Aug. 23, 2026. GuruFocus rates TXG with a GF Score™ of 56/100 and a GF Value™ of $18.37 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 684 Healthcare Providers & Services companies, 10x Genomics ranks worse than 93.42% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, 10x Genomics's Enterprise Value is $8,011.3 Mil.
10x Genomics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $127.1 Mil. Therefore, 10x Genomics's EV-to-OCF for today is 63.04.
The historical rank and industry rank for 10x Genomics's EV-to-OCF or its related term are showing as below:
TXG'
s EV-to-OCF Range Over the Past 10 Years
Min: -1112.59 Med: -89.44 Max: 361.66
Current: 63.04
During the past 9 years, the highest EV-to-OCF of 10x Genomics was 361.66. The lowest was -1112.59. And the median was -89.44.
TXG's EV-to-OCF is ranked worse than 93.42% of 684
companies
in the Healthcare Providers & Services industry
Industry Median: 8.865
vs TXG: 63.04
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
10x Genomics's PE Ratio (TTM) for today is calculated as:
10x Genomics's share price for today is $65.12.
10x Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.590.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
10x Genomics EV-to-OCF Related Terms
10x Genomics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for 10x Genomics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, 10x Genomics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics EV-to-OCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where 10x Genomics's EV-to-OCF falls into.
10x Genomics's current Enterprise Value is $8,011.3 Mil.
10x Genomics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $127.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (TXG) has a EV-to-OCF of 63.04 as of Aug. 23, 2026. According to the industry distribution chart, 10x Genomics ranks #639 out of 684 companies in the Healthcare Providers & Services industry, placing it in the top 93.4%.
Is 10x Genomics' EV-to-OCF too high?
10x Genomics' current EV-to-OCF is 63.04. The Healthcare Providers & Services industry median EV-to-OCF is 8.87. 10x Genomics' value of 63.04 is 611.1% above this industry median. Based on the distribution chart, 10x Genomics ranks #639 out of 684 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, 10x Genomics has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' EV-to-OCF compare to HNGE and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #639 out of 684 companies for EV-to-OCF. This places 10x Genomics in the lower half of its industry. The industry median EV-to-OCF is 8.87. 10x Genomics' value of 63.04 is 611.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Healthcare Providers & Services company?
The median EV-to-OCF among Healthcare Providers & Services companies is 8.87, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 10x Genomics's current EV-to-OCF of 63.04 is 611.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median EV-to-OCF is 8.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current EV-to-OCF is 63.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.37, compared to a current price of $65.12 — trading 254.5% above its estimated fair value. The current EV-to-OCF is 63.04 and 611.1% above the Healthcare Providers & Services industry median of 8.87. 10x Genomics' overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For 10x Genomics (TXG), the current EV-to-OCF is 63.04 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $65.12 is trading 254.5% above its estimated GF Value™ of $18.37.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
EV-to-OCF: 63.04
GF Value™: $18.37 vs. price of $65.12 (254.5% above fair value)
Industry Position: 611.1% above the Healthcare Providers & Services median (#639 of 684)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
56GF Score
Get the complete analysis for TXG
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
